Telix Pharmaceuticals Ltd
TLX101-Px
brain cancer
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews TLX101-Px for brain cancer around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“In February 2026, we submitted a Marketing Authorization Application ("MAA") for TLX101-Px in Europe, with France acting as the Reference Member State ("RMS").”